ART Fertility Clinics partners with Conceivable Life Sciences to explore robotic IVF technology in Abu Dhabi
The proposed collaboration covers laboratory infrastructure, workflow integration, training for clinical and laboratory teams, and the validation and regulatory requirements for potential deployment.
UAE—ART Fertility Clinics has signed a memorandum of understanding (MoU) with US-based Conceivable Life Sciences at the Abu Dhabi Future Health Summit 2026 to explore the use of robotics and artificial intelligence (AI) in fertility treatment.
The agreement will assess the feasibility of introducing Conceivable Life Sciences’ AURA platform at IVI Institute in Abu Dhabi.
The proposed collaboration covers laboratory infrastructure, workflow integration, training for clinical and laboratory teams, and the validation and regulatory requirements for potential deployment.
The agreement was signed by Suresh Soni, Chief Executive Officer of ART Fertility Clinics, and Dr. Alejandro Chávez-Badiola, Chief Medical Officer and Co-Founder of Conceivable Life Sciences, in the presence of H.E. Dr. Noura Al Ghaithi, Undersecretary of the Department of Health Abu Dhabi.
Robotics enters IVF laboratory workflows
AURA combines robotics, Physical AI, advanced imaging and software to automate selected procedures in IVF laboratories.
The platform is designed to improve precision, consistency and traceability in laboratory processes while keeping embryologists responsible for supervision and clinical decisions.
H.E. Dr. Khuloud Al-Dhalei, Executive Director of the Healthcare Quality Sector at the Department of Health Abu Dhabi, said the partnership supports the Emirate’s efforts to assess how emerging technologies can improve reproductive healthcare while maintaining patient safety and specialist oversight.
Soni noted that the proposed collaboration aligns with the development of the IVI Institute as a centre for advanced fertility treatment.
He said automation could improve consistency in laboratory operations while allowing embryologists and clinicians to retain responsibility for patient care.
Alan Murray, Chief Executive Officer and Co-Founder of Conceivable Life Sciences, said the agreement provides a framework for assessing how AURA could fit into ART Fertility Clinics’ laboratory operations and support patients in the region.
The platform targets delicate and repetitive laboratory procedures that require precision and consistency.
Dr. Chávez-Badiola said IVF still involves several manual procedures performed under time constraints.
He explained that AURA aims to create more controlled, standardised and traceable laboratory processes, with automation supporting rather than replacing embryologists.
Abu Dhabi expands reproductive health strategy
The partnership forms part of Abu Dhabi’s broader investment in reproductive healthcare, research and medical technology.
Through the Abu Dhabi Programme for the Future of Reproductive Health, genetic screening initiatives and the Global Reproductive Health Advisory Council, the Emirate is developing services spanning prevention, fertility treatment and research.
For the fertility industry, the proposed evaluation highlights the growing role of automation in standardising laboratory procedures.
However, regulatory validation, clinical oversight, workforce training and patient safety will remain important considerations before such technologies enter routine practice.
The agreement was announced during Abu Dhabi Future Health Summit 2026, the annual flagship gathering of Future Health, a global initiative convened by the Department of Health Abu Dhabi and its founding partners: PureHealth, M42, Institute for Healthier Living Abu Dhabi and Mubadala BIO.
Held under the theme To Sense Is to Predict, the summit focuses on longevity and precision health, digital health and AI, health system resilience and sustainability, and investment in life sciences.
Be the first to leave a comment